

Amendments to Claims

Kindly amend claims 1-4, 9, 14, and 15, as indicated in the following complete listing of claims:

Listing of Claims

1. (currently amended) An isolated antibody that specifically binds to human P210 BCR-ABL fusion protein ~~junction~~ (SEQ ID NO: 1), but does not bind wild type BCR or wild type c-ABL.
2. (currently amended) The antibody of claim 1, wherein said antibody binds a P210 BCR-ABL polypeptide comprising fusion joint residues 94 to 108 of SEQ ID NO: 1.
3. (currently amended) The antibody of claim 1, wherein said antibody binds a P210 BCR-ABL polypeptide comprising fusion joint residues 97 to 101 of SEQ ID NO: 1.
4. (currently amended) The antibody of claim 1, wherein said antibody is ~~polyclonal~~ suitable for specifically detecting P210 BCR-ABL fusion protein in a cell-based assay selected from the group consisting of flow cytometry (FC), immunohistochemistry (IHC), or immunofluorescence (IF).
5. (original) The antibody of claim 1, wherein said antibody is monoclonal.
6. (original) An immortalized cell line producing the antibody of claim 5.
7. (original) The cell line of claim 6, wherein said cell line is a hybridoma.
8. (original) The cell line of claim 7, wherein said hybridoma is ATCC Accession No. PTA-5851.

9. (currently amended) A method for detecting the presence of P210 BCR-ABL fusion protein in a biological sample, said method comprising the steps of:

- (a) contacting a biological sample potentially, or suspected of, containing P210 BCR-ABL fusion protein with at least one antibody of claim 1, under conditions suitable for formation of an antibody-BCR-ABL fusion protein complex; and
- (b) detecting the presence of said complex in said biological sample, wherein the presence of said complex indicates the presence of P210 BCR-ABL fusion protein in said sample.

10. (original) The method of claim 9, wherein said biological sample is obtained from a subject at risk of, or suspected of, having a disease involving BCR-ABL fusion protein expression.

11. (original) The method of claim 10, wherein said disease is chronic myelogenous leukemia (CML).

12. (original) The method of claim 9, wherein said biological sample has been contacted with at least one BCR-ABL inhibitor, or is obtained from a subject treated with such inhibitor.

13. (original) The method of claim 9, wherein said biological sample has been contacted with a compound being tested for inhibition of BCR-ABL activity or expression.

14. (currently amended) A method for identifying a compound that modulates expression of P210 BCR-ABL fusion protein in a biological sample, said method comprising the steps of:

- (a) contacting a test biological sample with a test compound,
- (b) detecting the level of P210 BCR-ABL fusion protein in said test biological sample of step (a) using at least one antibody of claim 1 under conditions suitable for formation of an antibody-BCR-ABL fusion protein complex, and

(c) comparing the level of P210 BCR-ABL fusion protein detected in step (b) with the presence of P210 BCR-ABL fusion protein in a control sample not contacted with said test compound, wherein a difference in P210 BCR-ABL fusion protein levels in said test and control samples identifies said compound as a compound that modulates expression of P210 BCR-ABL fusion protein.

15. (currently amended) A kit for the detection of P210 BCR-ABL fusion protein in a biological sample, said kit comprising (a) at least one detectable antibody of claim 1 and (b) at least one secondary antibody conjugated to a detectable group.